References
- Altuvia S, Stein WD, Goldenberg S, et al. (1993). Targeted disruption of the mouse mdr1b gene reveals that steroid hormones enhance mdr gene expression. J Biol Chem 268:27127–32.
- Bodor M, Kelly EJ, Ho RJ. (2005). Characterization of the human MDR1 gene. AAPS J 7:1–5.
- Cascorbi I. (2006). Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 112:457–73.
- Chinn LW, Kroetz DL. (2007). ABCB1 pharmacogenetics: progress, profiles, and promise. Clin Pharmacol Ther 81:265–9.
- Drozdzik M, Bialecka M, Mysliwiec K, et al. (2003). Polymorphism in the P-glycoprotein drug transporter ABCB1 gene: a possible link between environmental and genetic factors in Parkinson’s disease. Pharmacogenentics 13:259–63.
- Erica L, Woodahl H, Crouthamel J, et al. (2009). MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol 64:183–8.
- Fromm MF. (2002). The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 54:1295–310.
- Germann UA. (1996). P-glycoprotein—a mediator of multidrug resistance in tumour cells. Eur J Cancer 32:927–44.
- Haufroid V. (2011). Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition. Curr Drug Targets 12:631–46.
- Hoffmeyer S, Burk O, von Richter O, et al. (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473–8.
- Kalken CK, Broxterman HJ, Pinedo HM, et al. (1993). Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br J Cancer 67:284–9.
- Khabour OF, Alzoubi KH, Azzam SI, et al. (2013). Frequency of MDR1 single nucleotide polymorphisms in a Jordanian population, including a novel variant. Genet Mol Res 12:801–8.
- Kim RB, Leake BF, Choo EF, et al. (2001). Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189–99.
- Lin JH, Yamazaki M. (2003). Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42:59–98.
- Matthew N, Pepita G, Emma S, et al. (2004). P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate 59:77–90.
- Peng R, Zhang H, Zhang Y, et al. (2015a). Effects of the ABCB1 (1199G > A) polymorphism on steroid sex hormone-induced P-glycoprotein expression, ATPase activity, and hormone efflux. Med Sci 3:124–37.
- Peng R, Zhang H, Zhang Y, et al. (2015b). Establishment of HEK293 cell lines stably transfected with ABCB1 (G1199A) gene. Chin Hosp Pharm J 35:2110–15.
- Sakaeda T, Nakamura T, Okumura K. (2003). Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4:397–410.
- Salama NN, Yang Z, Bui T, et al. (2006). MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci 95:2293–308.
- Ueda K, Okamura N, Hirai M, et al. (1992). Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267:24248–52.
- Uhr M, Holsboer F, Muller MB. (2002). Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J Neuroendocrinol 14:753–9.
- Winnie Y, Leslie Z. (2004). P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression In Vitro. Pharm Res 21:1248–93.
- Woodahl EL, Yang Z, Bui T, et al. (2004). Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. J Pharmacol Exp Ther 310:1199–207.